Pipeline
One lead program. Two disease branches.
NVP-13 connects neurodegeneration and fibrosis through the hypothesis of modulating pathological TGF-β signaling.
| Program / target | Disease branch | Public evidence |
|---|---|---|
| NVP-13TGFBR2 · Antisense | Neurodegeneration | Published preclinical research Current development-stage wording awaits company confirmation. |
| NVP-13TGFBR2 · Antisense | Fibrosis | Therapeutic hypothesis Indication-specific development status awaits company confirmation. |
The cited publications do not establish the current IND, clinical-trial or regulatory status.
Current stages require approval of dated, public evidence. Additional programs will be included only after their public scope is confirmed.
Explore NVP-13